Tasquinimod and paquinimod blocked the S100a8/a9‐Tlr4‐Nfκb signaling pathway, improved renal function, and reduced mortality, and also decreased inflammatory monocytes infiltration, ameliorated kidney injury phenotype, and prevented long‐term renal fibrosis. This evidence concerns the gene TLR4 and renal fibrosis.